Clinical Efficacy and Safety of Oral Decitabine/Cedazuridine in 133 Patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)

[Image: see text] Introduction: Hypomethylating agents (HMAs) or DNA methyltransferase inhibitors (DNMTi) such as decitabine or azacitidine are established standard of care for the treatment of MDS and CMML. The oral bioavailability of these agents has been limited due to rapid degradation by cytidi...

Descripción completa

Detalles Bibliográficos
Autores principales: Savona, Michael R., McCloskey, James K., Griffiths, Elizabeth A., Yee, Karen W.L., Al-Kali, Aref, Zeidan, Amer M., Deeg, H. Joachim, Patel, Prapti A., Sabloff, Mitchell, Keating, Mary-Margaret, Dao, Kim-Hien, Zhu, Nancy, Gabrail, Nashat, Fazal, Salman, Maly, Joseph, Odenike, Olatoyosi, Kantarjian, Hagop M., DeZern, Amy E., O'Connell, Casey L., Roboz, Gail J., Busque, Lambert, Wells, Richard A., Amin, Harshad, Randhawa, Jasleen K., Leber, Brian, Hao, Yong, Keer, Harold N., Azab, Mohammad, Garcia-Manero, Guillermo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology. Published by Elsevier Inc. 2020
Materias:
637. Myelodysplastic Syndromes—Clinical Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330281/
http://dx.doi.org/10.1182/blood-2020-133855

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330281/
http://dx.doi.org/10.1182/blood-2020-133855

Ejemplares similares